Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) investors have a smile on their faces Monday evening, after the drug maker announced positive Phase 2 results for …
William Blair analyst John Sonnier is out highlighting standout insights from his 37th Annual Growth Stock Conference held yesterday. Gilead Sciences, Inc.
Earnings season always brings surprises and serves as a catalyst for companies. In light of yesterday’s reports, Oppenheimer analysts remain cautious on Advanced …
Exelixis, Inc. (NASDAQ:EXEL) announced that the FDA has granted orphan drug designation to cabozantinib for the treatment of hepatocellular carcinoma (HCC).
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Exelixis, Inc. (NASDAQ:EXEL) have stirred up interest after Valeant has stepped closer to FDA approval for Vesneo …
Exelixis, Inc. (NASDAQ:EXEL) reported financial results for the fourth quarter and full year of 2016 and provided an update on progress toward delivering …
Exelixis, Inc. (NASDAQ:EXEL) announced a new collaboration with Roche on a phase 1b dose escalation study that will evaluate the safety and tolerability …
Exelixis, Inc. (NASDAQ:EXEL) and Takeda Pharmaceutical announced an exclusive licensing agreement for the commercialization and further clinical development in Japan of cabozantinib, Exelixis’ …
As he previews fourth-quarter results for these two biotech giants, William Blair analyst John Sonnier is setting positive expectations on Gilead Sciences, Inc. (NASDAQ:GILD) …
As earnings season rolls to the foreground and key biotech players like Gilead Sciences, Inc. (NASDAQ:GILD), Merrimack Pharmaceuticals Inc (NASDAQ:MACK), ACADIA Pharmaceuticals Inc.
